Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
October 04, 2023 08:30 ET
|
Kineta, Inc.
SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
October 04, 2023 08:00 ET
|
Kineta, Inc.
SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in...
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
October 03, 2023 08:30 ET
|
Kineta, Inc.
Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level >90% VISTA Receptor Occupancy Observed in the 30 mg Dosing...
Kineta Announces Participation at October Investor Conferences
September 28, 2023 09:30 ET
|
Kineta, Inc.
SEATTLE, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
September 25, 2023 09:30 ET
|
Kineta, Inc.
SEATTLE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression
September 18, 2023 09:30 ET
|
Kineta, Inc.
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta to Participate in Upcoming Investor Conferences
August 31, 2023 09:30 ET
|
Kineta, Inc.
SEATTLE, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 11, 2023 16:01 ET
|
Kineta, Inc.
Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration...
Kineta to Receive $5 Million Milestone Payment from Merck
June 29, 2023 06:30 ET
|
Kineta, Inc.
SEATTLE, June 29, 2023 (GLOBE NEWSWIRE) -- (June 29, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that...
Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
June 28, 2023 06:30 ET
|
Kineta, Inc.
SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...